Sarepta Therapeutics Inc (SRPT) : Perceptive Advisors reduced its stake in Sarepta Therapeutics Inc by 1.72% during the most recent quarter end. The investment management company now holds a total of 3,767,316 shares of Sarepta Therapeutics Inc which is valued at $95,162,402 after selling 65,812 shares in Sarepta Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Sarepta Therapeutics Inc makes up approximately 6.97% of Perceptive Advisors’s portfolio.
Other Hedge Funds, Including , Lehman Financial Resources sold out all of its stake in SRPT during the most recent quarter. The investment firm sold 41,311 shares of SRPT which is valued $1,043,516. Hudson Bay Capital Management Lp added SRPT to its portfolio by purchasing 455,000 company shares during the most recent quarter which is valued at $11,493,300. Sarepta Therapeutics Inc makes up approx 1.12% of Hudson Bay Capital Management Lp’s portfolio.Integrated Wealth Management reduced its stake in SRPT by selling 500 shares or 98.04% in the most recent quarter. The Hedge Fund company now holds 10 shares of SRPT which is valued at $272.Public Employees Retirement Association Of Colorado reduced its stake in SRPT by selling 124 shares or 1.0% in the most recent quarter. The Hedge Fund company now holds 12,338 shares of SRPT which is valued at $311,905.Cutler Group Lp boosted its stake in SRPT in the latest quarter, The investment management firm added 59,021 additional shares and now holds a total of 155,202 shares of Sarepta Therapeutics Inc which is valued at $3,310,459. Sarepta Therapeutics Inc makes up approx 0.22% of Cutler Group Lp’s portfolio.
Sarepta Therapeutics Inc opened for trading at $26.11 and hit $26.38 on the upside on Tuesday, eventually ending the session at $26.24, with a gain of 0.50% or 0.13 points. The heightened volatility saw the trading volume jump to 14,36,090 shares. Company has a market cap of $1,257 M.
On the company’s financial health, Sarepta Therapeutics Inc reported $-1.19 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $-1.21.Analysts expectations of $ .10.During the same quarter in the previous year, the company posted $-0.87 EPS.
Many Wall Street Analysts have commented on Sarepta Therapeutics Inc. Company shares were Reiterated by Needham on Jul 22, 2016 to “Buy”, Firm has raised the Price Target to $ 26 from a previous price target of $20 .Sarepta Therapeutics Inc was Upgraded by Piper Jaffray to ” Neutral” on Jun 9, 2016. Wedbush Upgraded Sarepta Therapeutics Inc on Jun 7, 2016 to ” Outperform”, Price Target of the shares are set at $36.
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.